CD276 and cancer: Our earlier work reported the creation of ADCs targeting CD276 (B7-H3), a cell-surface molecule widely overexpressed in cancer cells and tumor-associated stromal cells across various cancers, including breast, colon, and lung carcinomas.13,14 Overexpression of CD276 in tumors is widely associated with a worse prognosis.